---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-007186"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2023-01-12T23:59:59+00:00"
generated_at: "2026-06-20T16:08:10.586199+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Biomea Fusion details 2023 milestones: AML/ALL data, KRAS trial, diabetes data, BMF-500 IND

## Summary
- Plan to present initial COVALENT-101 data (BMF-219 in AML/ALL) in H1 2023; first patient in COVALENT-102 (KRAS solid tumors) dosed Jan 2023.
- IND for BMF-500 (FLT3 inhibitor) expected in H1 2023 for COVALENT-103 trial in acute leukemia.
- Phase II COVALENT-111 (BMF-219 in Type 2 diabetes) initial data from first two cohorts by end of Q1 2023.
- Third development candidate from FUSION platform to be announced in H1 2023.
- BMF-219 is first menin inhibitor in clinical development for solid tumors and diabetes.

## SEC filing metadata
- accession: 0001193125-23-007186
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2023-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312523007186/0001193125-23-007186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312523007186/d417295d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-007186
- JSON: https://secwatch.observer/filing/0001193125-23-007186.json
- Plain text: https://secwatch.observer/filing/0001193125-23-007186.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.